InnoCare Pharma(688428) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

CN Stock MarketDetailed Quotes

688428 InnoCare Pharma

Watchlist

17.79
+0.10+0.57%

Trading Mar 18 09:55 CST

31.36BMarket Cap-83.52P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

An Intrinsic Calculation For InnoCare Pharma Limited (HKG:9969) Suggests It's 49% Undervalued
Simply Wall StMar 17 01:10 ET
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Zhitong FinanceMar 16 21:18 ET
InnoCare Pharma Schedules Board Meeting for Annual Results Approval
TipRanksMar 14 05:45 ET
INNOCARE (09969.HK) plans to hold a Board of Directors meeting on March 27 to approve the annual performance.
Gelonghui, March 14丨INNOCARE (09969.HK) announced that the Board of Directors will hold a meeting on March 27, 2025 (Thursday) to consider and approve the annual performance of the company and its subsidiaries for the year ending December 31, 2024, and its release.
Gelonghui FinanceMar 14 05:22 ET
INNOCARE: DATE OF BOARD MEETING
HKEXMar 14 05:05 ET · Announcements
Trending Industry Today: WUXI BIO Leads Gains In Biotechnology Stocks
Moomoo NewsMar 13 23:30 ET

Comments

INNOCARE

May 21, 2024 11:57

Columns InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for CLL/SLL in China

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therap...

INNOCARE

May 16, 2024 09:28

Columns InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
This is a multicente...

INNOCARE

Apr 26, 2024 17:56

Columns InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the release of its 2023 Environmental, Social, and Corporate Governance (ESG) report. This marks the fifth year InnoCare has issued its ESG report, and the first year InnoCare has set up specific environmental management targets.
In the...

INNOCARE

Apr 18, 2024 09:35

Columns Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

$INNOCARE (09969.HK)$ $InnoCare Pharma (688428.SH)$ The American Journal of Hematology recently published the results of a phase II study of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with patients with persistent or chronic primary immune thrombocytopenia (ITP), which evaluated the efficacy and safety of orelabrutinib in adult patients with persistent or chronic ITP. The jour...

INNOCARE

Mar 29, 2024 08:44

Columns InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

InnoCare Pharma ( $INNOCARE (09969.HK)$ $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare’s novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor, ICP-189, with ArriVent’s furmonertin...